Investigate the pharmacokinetic drug interactions between gemigliptin and rosuvastatin in healthy subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
gemigliptin 50mg qd on day 1\~7
rosuvastatin 20mg qd on day 1\~7
gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
Asan Medical Center
Seoul, South Korea
Cmax
to evaluate Cmax of gemigliptin and rosuvastatin at steady state
Time frame: up to 72 hour post dose
AUC
to evaluate AUCt of gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin at steady state
Time frame: up to 72 hour post dose
Tmax
to evaluate time of Cmax at steady state, gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin
Time frame: up to 72 hour post dose
Cmin
to evaluate Cmin of gemigliptin and rosuvastatin at steady state
Time frame: upto 72 hour post dose
t1/2β
to evaluate half-life of gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin
Time frame: upto 72 hour post dose
Cmax
to evaluate Cmax of metabolite LC15-0636, N-desmethylrosuvastatin at steady state
Time frame: upto 72 hour post dose
AUC
to evaluate AUC of metabolite LC15-0636, N-desmethylrosuvastatin at steady state
Time frame: upto 72 hour post dose
metabolic ratio
to evaluate metabolic ratio of gemiglipin and rosuvastatin
Time frame: upto 72 hour post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.